Referencia número: HY-B0277

Vidarabine

Name: Vidarabine
Brand: MedChemExpress
SKU: HY-B0277
Price: 48.00 USD
Availability: InStock
Rating: 5 (8 reviews)

(Synonyms: Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine)

8 Cited Publications

Revisión del cliente

Based on 8 publication(s) in Google Scholar

Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 98.85%
No. CAS: 5536-17-4
Fòrmula: C₁₀H₁₃N₅O₄
Peso molecular:267.25

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Vidarabine Chemical Structure

No. CAS: 5536-17-4

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (8)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas DNA/RNA Synthesis :

Ver todos los productos específicos de isoformas HSV :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	62 nM Compound: ara-A, vidarabine	Inhibition of human DPP4 from human Caco-2 cells Inhibition of human DPP4 from human Caco-2 cells	[PMID: 20000418]
CCRF-CEM	IC₅₀	24.8 μM Compound: ara A	Antitumor activity was evaluated against CEM cell line Antitumor activity was evaluated against CEM cell line	[PMID: 9871764]
CCRF-CEM	IC₅₀	24.8 μM Compound: araA	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
CCRF-HSB-2	IC₅₀	12.9 μg/mL Compound: araA	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
HEL	EC₅₀	10 μM Compound: ara-A, vidarabine	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin	[PMID: 20000418]
HEL	EC₅₀	35 μM Compound: ara-A, vidarabine	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20000418]
HEL	EC₅₀	42 μM Compound: ara-A, vidarabine	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin	[PMID: 20000418]
HEL	EC₅₀	8.3 μM Compound: ara-A, vidarabine	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20000418]
HEL	ED₅₀	1.17 μg/mL Compound: araA	Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	17.1 μg/mL Compound: araA	Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	6.45 μg/mL Compound: araA	Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	6.6 μg/mL Compound: araA	Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HFF	CC₅₀	>100 μM Compound: 1	Cytotoxicity against HFF Cytotoxicity against HFF	[PMID: 19097789]
HFF	CC₅₀	90 μM Compound: 1	Cytotoxicity against HFF in presence of deoxy-coformycin Cytotoxicity against HFF in presence of deoxy-coformycin	[PMID: 19097789]
HFF	IC₅₀	2 μM Compound: Ara-A	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HL-60	IC₅₀	20.9 μg/mL Compound: ara-A	The cytotoxic activity in HL-60 cells The cytotoxic activity in HL-60 cells	[PMID: 9371251]
KB	IC₅₀	39 μg/mL Compound: ara-A	In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells	[PMID: 2838633]
KB	IC₅₀	5.6 μg/mL Compound: ara-A	Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells	[PMID: 2838633]
L1210	IC₅₀	14.2 μM Compound: ara A	Antitumor activity was evaluated against L1210 cell line Antitumor activity was evaluated against L1210 cell line	[PMID: 9871764]
L1210	IC₅₀	14.2 μM Compound: araA	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
MOLT-4	IC₅₀	11.9 μM Compound: ara A	Antitumor activity was evaluated against Molt4/C8 cell line Antitumor activity was evaluated against Molt4/C8 cell line	[PMID: 9871764]
MOLT-4	IC₅₀	11.9 μM Compound: araA	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
PRK	IC₅₀	0.4 μg/mL Compound: ara-A	Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [1,'2'-3H]dUrd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [1,'2'-3H]dUrd	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [Me-3H]-dThd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [Me-3H]-dThd	[PMID: 6267280]
PRK	IC₅₀	10 μg/mL Compound: ara-A	Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	10 μg/mL Compound: ara-A	Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells	[PMID: 6267280]
PRK	IC₅₀	20 μg/mL Compound: ara-A	Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	3 μg/mL Compound: ara-A	Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 2-4 Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 2-4	[PMID: 6267280]
PRK	IC₅₀	4 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured	[PMID: 6267280]
PRK	IC₅₀	7 μg/mL Compound: ara-A	Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 4-10 Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 4-10	[PMID: 6267280]
Vero	CC₅₀	38 μM Compound: araA	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	28 μM Compound: araA	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	35 μM Compound: araA	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	37.8 μM Compound: VDB	Antiviral activity against thymidine kinase deficient Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against thymidine kinase deficient Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	46.1 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells harboring stop mutation thymidine kinase by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells harboring stop mutation thymidine kinase by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	7 μM Compound: araA	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]

In Vitro

Vidarabine inhibits herpes simplex virus, varicella-zoster virus, and cytomegalovirus in in vitro cell culture systems^[1].
Vidarabine exerts its antiviral effect via phosphorylation to a triphosphate derivative that competitively inhibits DNA polymerase and is incorporated into terminal positions of growing DNA molecules^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vidarabine (3%; topical to the eye; four times daily) supports normal corneal epithelial wound healing in rabbits, with epithelial quality significantly superior to Idoxuridine (HY-B0307) and comparable to placebo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

unspecified strain^[1]
Dosage:

3%
Administration:

topical to the eye; four times daily
Result:

Achieved complete healing of 5 mm corneal lesions by 60 hours, with no significant difference in healing rate compared to placebo or idoxuridine.
Achieved complete healing of 10 mm corneal lesions by 8 days, with no significant difference in healing rate compared to placebo or idoxuridine.
Showed significantly better regenerated epithelium quality (lower scores) than idoxuridine-treated eyes on days 4 and 7 (p = 0.05), with results comparable to placebo.
Demonstrated less severe histological abnormalities compared to idoxuridine-treated eyes.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 5536-17-4
Appearance Solid
Peso molecular 267.25
Fòrmula C₁₀H₁₃N₅O₄
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1
Synonyms

Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine
Structure Classification
Initial Source
- Microorganisms
Streptomyces
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cells

Shikonin Inhibits Fin Regeneration in Zebrafish Larvae. [Abstract]

2022 Oct 11;11(20):3187. PMID: 36291055
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cell Signal

TP53 links mitochondria-endoplasmic reticulum crosstalk and ferroptosis in septic cardiomyopathy: Protective modulation by nicorandil. [Abstract]

2026 Aug:144:112537. PMID: 41997516
J Cell Physiol

C1q/tumor necrosis factor-related protein-6 attenuates TNF-α-induced apoptosis in salivary acinar cells via AMPK/SIRT1-modulated miR-34a-5p expression. [Abstract]

2021 Aug;236(8):5785-5800. PMID: 33400820
Int J Biochem Cell Biol

C1q/tumour necrosis factor-related protein-3 alleviates high-glucose-induced lipid accumulation and necroinflammation in renal tubular cells by activating the adenosine monophosphate-activated protein kinase pathway. [Abstract]

2022 Aug:149:106247. PMID: 35753650
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
bioRxiv

2020 Apr.

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (187.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7418 mL

18.7091 mL

37.4181 mL

5 mM

0.7484 mL

3.7418 mL

7.4836 mL

10 mM

0.3742 mL

1.8709 mL

3.7418 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (282 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Whitley R, et al. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1980 Oct;20(4):267-82. [Content Brief]

[2]. VanLandingham KE, et al. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988;259(7):1051-1053. [Content Brief]

[3]. Stolk LM, et al. Formulation of a stable vidarabine infusion fluid. Pharm Weekbl Sci. 1983;5(2):57-60. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7418 mL	18.7091 mL	37.4181 mL	93.5454 mL
	5 mM	0.7484 mL	3.7418 mL	7.4836 mL	18.7091 mL
	10 mM	0.3742 mL	1.8709 mL	3.7418 mL	9.3545 mL
	15 mM	0.2495 mL	1.2473 mL	2.4945 mL	6.2364 mL
	20 mM	0.1871 mL	0.9355 mL	1.8709 mL	4.6773 mL
	25 mM	0.1497 mL	0.7484 mL	1.4967 mL	3.7418 mL
	30 mM	0.1247 mL	0.6236 mL	1.2473 mL	3.1182 mL
	40 mM	0.0935 mL	0.4677 mL	0.9355 mL	2.3386 mL
	50 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8709 mL
	60 mM	0.0624 mL	0.3118 mL	0.6236 mL	1.5591 mL
	80 mM	0.0468 mL	0.2339 mL	0.4677 mL	1.1693 mL
	100 mM	0.0374 mL	0.1871 mL	0.3742 mL	0.9355 mL

Bioz

Vidarabine

8 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Vidarabine

Publications Citing Use of MedChemExpress (MCE) Vidarabine

Ver todos los productos específicos de isoformas DNA/RNA Synthesis

Ver todos los productos específicos de isoformas HSV